A Phase 2 interventional study of Andecaliximab and Placebo in Crohn's Disease, sponsored by Gilead Sciences. Terminated at 74 sites in 13 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-04-23.
Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 660 studies in Crohn Disease with a site in United States — 122 open to participants now, 163 under way, 35 of them phase 3. Crohn Disease · United States.
Among the 660 studies in Crohn Disease with a site in United States, this one is the 139th largest by enrollment of the 528 interventional ones that give a count, is one of 30 that started in 2015, is one of 141 in phase 2, and was the 282nd registered.
1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.
Browse Crohn Disease studies →122 of the 660 studies in Crohn Disease with a site in United States are open now. Recruiting first, the newest first:
Shattuck Labs, Inc. · Sites in United States
Ages 18–80
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Sites in United States
Ages 18–85
Agomab Spain S.L.U. · Sites in United States, Serbia, United Kingdom
Ages 18+
University of Miami · Sites in United States
Ages 16–75
The Cleveland Clinic · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
660 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 86 · Phase 2 179 · Phase 3 134 · Phase 4 41
First in 1995; this study’s year is marked. 30 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 187 is above the median of 67 across 1,261 interventional studies indexed under Crohn Disease.
Median enrollment 60 across the 528 interventional studies, 168 across the 128 observational. Of the 452 that completed or were terminated, 205 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
310 of 660 have an industry lead sponsor. The 10 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
Gilead Sciences has 3 studies filed under Crohn Disease — fewer than ten, so there is no comparison to draw.
59 of the studies in Crohn Disease with a site in United States that are under way reach primary completion within a year, 9 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06063967Phase 3AbbVieA Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease. | 2027-03 |
| NCT05347095Phase 3Janssen-Cilag Ltd.A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease | 2027-03-25 |
| NCT05660746Phase 3Children's Hospital Medical Center, CincinnatiPrecise Infliximab Exposure and Pharmacodynamic Control | 2027-03-31 |
| NCT06408935Phase 3Janssen-Cilag Ltd.Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients | 2027-06-08 |
| NCT06227910Phase 3TakedaA Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease | 2027-06-08 |
Add all 59 to your calendar (.ics) → With an account.
Among the 660 studies in Crohn Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will primarily evaluate the safety and efficacy of andecaliximab in adults with active Crohn's disease. The study will consist of a Double-Blind Phase of 8 weeks followed by an Open-Label Extension. Participants who complete the Double-Blind Phase will be eligible to enroll in the optional Open-Label Extension for an additional 44 weeks. Participants who complete Week 52 assessments will be eligible to enter the Extended Treatment Phase to continue treatment with andecaliximab for an additional 156 weeks.
Key Inclusion Criteria:
Within the previous 5 years, demonstrated an inadequate clinical response or intolerance of at least one of the following agents:
May be receiving the following drugs:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/ Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Double-Blind Phase: Participants will receive 1 single-use prefilled syringe (PFS) of andecaliximab 150 mg and matching placebo coadministered at Weeks 0, 2, 4, and 6 and 2 single-use PFS of placebo coadministered at Weeks 1, 3, 5, and 7. Open-Label Phase: Participants will be eligible to enroll in the Open-Label Phase to receive andecaliximab 150 mg weekly for an additional 44 weeks. Extended Treatment Phase: Participants who complete Week 52 assessments will be eligible to enter into the Extended Treatment Phase to continue treatment with andecaliximab 150 mg for an additional 156 weeks.
Drug: Andecaliximab · Drug: Placebo
Double-Blind Phase: Participants will receive 1 single-use PFS of andecaliximab 150 mg and matching placebo coadministered weekly for 8 weeks. Open-Label Phase: Participants will be eligible to enroll in the Open-Label Phase to receive andecaliximab 150 mg weekly for an additional 44 weeks. Extended Treatment Phase: Participants who complete Week 52 assessments will be eligible to enter into the Extended Treatment Phase to continue treatment with andecaliximab 150 mg for an additional 156 weeks.
Drug: Andecaliximab · Drug: Placebo
Double-Blind Phase: Participants will receive 2 single-use PFS of andecaliximab 150 mg coadministered weekly for 8 weeks. Open-Label Phase: Participants will be eligible to enroll in the Open-Label Phase to receive andecaliximab 150 mg weekly for an additional 44 weeks. Extended Treatment Phase: Participants who complete Week 52 assessments will be eligible to enter into the Extended Treatment Phase to continue treatment with andecaliximab 150 mg for an additional 156 weeks.
Drug: Andecaliximab
Double-Blind Phase: Participants will receive 2 single-use PFS of placebo coadministered weekly for 8 weeks. Open-Label Phase: Participants will be eligible to enroll in the Open-Label Phase to receive andecaliximab 150 mg weekly for 44 weeks. Extended Treatment Phase: Participants who complete Week 52 assessments will be eligible to enter into the Extended Treatment Phase to continue treatment with andecaliximab 150 mg for an additional 156 weeks.
Drug: Andecaliximab · Drug: Placebo
Andecaliximab administered via subcutaneous (SC) injection
Also known as: GS-5745
Placebo to match andecaliximab administered via SC injection
Percentage of Participants Achieving Clinical Response (PRO2 Score ≤ 8) at Week 8 of the Double-Blind Phase
Clinical response was defined as patient-reported outcomes (PRO2) score ≤ 8 at Week 8. PRO2 is the weighted average of the 2 variables of frequency of liquid or very soft stool and abdominal pain, based on 7-day participant diary data. The PRO2 score has a minimum score of 0 and has no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain. Week 8 refers to the analysis window of Day 43 to Day 70 and prior to the first Open-Label dose date. Participants with a missing PRO2 value at the Week 8 analysis visit were imputed as not achieving the Clinical Response.
Time frame: Week 8
Percentage of Participants Achieving Endoscopic Response (≥ 50% Reduction From Baseline SES-CD) at Week 8 of the Double-Blind Phase
Endoscopic response was defined as ≥ 50% reduction from baseline in Simple Endoscopic Score for Crohn's Disease (SES-CD) at Week 8. The SES-CD evaluates 4 endoscopic variables: ulcer size, ulcerated surface, affected surface, and presence of narrowings. The total SES-CD is calculated as the sum of the 4 variables for the 5 bowel segments: rectum, left colon, transverse colon, right colon, and ileum. Scores range from 0 to 60, with higher scores indicating more severe disease. Week 8 refers to the analysis window of Day 43 to Day 70 and prior to the first Open-Label dose date. Participants with missing SES-CD value at Week 8 analysis visit were imputed as not achieving Endoscopic Response.
Time frame: Week 8
Percentage of Participants Achieving CDAI Remission (CDAI ≤ 150) at Week 8 of the Double-Blind Phase
Clinical remission was defined as Crohn's Disease Activity Index (CDAI) ≤ 150 at Week 8. CDAI is used as a measure of clinical response and remission. It includes 8 variables of patient-reported symptoms and objective variables: stool count, abdominal pain, general well-being, complications, use of anti-diarrheal medications, presence of abdominal mass, hematocrit values, and weight. It has a minimum range of 0 and no upper bound, with higher scores indicating greater disease activity. Week 8 refers to the analysis window of Day 43 to Day 70 and prior to the first Open-Label dose date. Participants with missing CDAI score at Week 8 analysis visit were imputed as not achieving CDAI Remission.
Time frame: Week 8
Percentage of Participants Achieving Mucosal Healing (SES-CD Size-of-Ulcer Subscore = 0) at Week 8 of the Double-Blind Phase
The SES-CD evaluates 4 endoscopic variables: ulcer size, ulcerated surface, affected surface, and presence of narrowings. The SES-CD size-of-ulcer subscore ranges from 0 (none) to 3 (very large). Mucosal healing at Week 8 was defined as the size-of-ulcer subscore for segments with non-zero baseline value changes to zero at Week 8 AND the size-of-ulcer subscore for segments with zero value at baseline remain zero at Week 8. Week 8 refers to the analysis window of Day 43 to Day 70 and prior to the first Open-Label dose date. Participants with missing SES-CD size-of-ulcer subscore at Week 8 analysis visit were imputed as not achieving Mucosal Healing.
Time frame: Week 8
Participants were enrolled at study sites in North America, Europe, South Africa, and Asia Pacific. The first participant was screened on 30 April 2015. The last study visit occurred on 22 December 2016.
| Milestone | Andecaliximab 150 mg Every 2 Weeks | Andecaliximab 150 mg Weekly | Andecaliximab 300 mg Weekly | Placebo |
|---|---|---|---|---|
| Started | 53 | 53 | 53 | 28 |
| Completed | 52 | 48 | 47 | 27 |
| Not completed | 1 | 5 | 6 | 1 |
| Withdrew: Adverse event | 0 | 2 | 4 | 1 |
| Withdrew: Withdrew consent | 0 | 1 | 2 | 0 |
| Withdrew: Study disease-related symptoms | 1 | 1 | 0 | 0 |
| Withdrew: Investigator's discretion | 0 | 1 | 0 | 0 |
| Milestone | Andecaliximab 150 mg Every 2 Weeks | Andecaliximab 150 mg Weekly | Andecaliximab 300 mg Weekly | Placebo |
|---|---|---|---|---|
| Started | 52 | 48 | 47 | 26 |
| Completed | 4 | 3 | 2 | 2 |
| Not completed | 48 | 45 | 45 | 24 |
| Withdrew: Study terminated by sponsor | 27 | 28 | 28 | 13 |
| Withdrew: Investigator's discretion | 14 | 11 | 11 | 2 |
| Withdrew: Adverse event | 6 | 1 | 2 | 6 |
| Withdrew: Study disease-related symptoms | 0 | 1 | 3 | 2 |
| Withdrew: Withdrew consent | 1 | 2 | 1 | 1 |
| Withdrew: Lack of efficacy | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 |
| Milestone | Andecaliximab 150 mg Every 2 Weeks | Andecaliximab 150 mg Weekly | Andecaliximab 300 mg Weekly | Placebo |
|---|---|---|---|---|
| Started | 3 | 2 | 2 | 2 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 3 | 2 | 2 | 2 |
| Withdrew: Study terminated by sponsor | 2 | 1 | 2 | 2 |
| Withdrew: Investigator's discretion | 0 | 1 | 0 | 0 |
| Withdrew: Study disease-related symptoms | 1 | 0 | 0 | 0 |
Clinical response was defined as patient-reported outcomes (PRO2) score ≤ 8 at Week 8. PRO2 is the weighted average of the 2 variables of frequency of liquid or very soft stool and abdominal pain, based on 7-day participant diary data. The PRO2 score has a minimum score of 0 and has no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain. Week 8 refers to the analysis window of Day 43 to Day 70 and prior to the first Open-Label dose date. Participants with a missing PRO2 value at the Week 8 analysis visit were imputed as not achieving the Clinical Response.
| percentage of participants | Andecaliximab 150 mg Every 2 Weeks | Andecaliximab 150 mg Weekly | Andecaliximab 300 mg Weekly | Placebo |
|---|---|---|---|---|
| Percentage of Participants Achieving Clinical Response (PRO2 Score ≤ 8) at Week 8 of the Double-Blind Phase | 17.0 (8.1 to 29.8) | 13.2 (5.5 to 25.3) | 11.3 (4.3 to 23.0) | 14.3 (4.0 to 32.7) |
Endoscopic response was defined as ≥ 50% reduction from baseline in Simple Endoscopic Score for Crohn's Disease (SES-CD) at Week 8. The SES-CD evaluates 4 endoscopic variables: ulcer size, ulcerated surface, affected surface, and presence of narrowings. The total SES-CD is calculated as the sum of the 4 variables for the 5 bowel segments: rectum, left colon, transverse colon, right colon, and ileum. Scores range from 0 to 60, with higher scores indicating more severe disease. Week 8 refers to the analysis window of Day 43 to Day 70 and prior to the first Open-Label dose date. Participants with missing SES-CD value at Week 8 analysis visit were imputed as not achieving Endoscopic Response.
| percentage of participants | Andecaliximab 150 mg Every 2 Weeks | Andecaliximab 150 mg Weekly | Andecaliximab 300 mg Weekly | Placebo |
|---|---|---|---|---|
| Percentage of Participants Achieving Endoscopic Response (≥ 50% Reduction From Baseline SES-CD) at Week 8 of the Double-Blind Phase | 11.3 (4.3 to 23.0) | 13.2 (5.5 to 25.3) | 7.5 (2.1 to 18.2) | 10.7 (2.3 to 28.2) |
Clinical remission was defined as Crohn's Disease Activity Index (CDAI) ≤ 150 at Week 8. CDAI is used as a measure of clinical response and remission. It includes 8 variables of patient-reported symptoms and objective variables: stool count, abdominal pain, general well-being, complications, use of anti-diarrheal medications, presence of abdominal mass, hematocrit values, and weight. It has a minimum range of 0 and no upper bound, with higher scores indicating greater disease activity. Week 8 refers to the analysis window of Day 43 to Day 70 and prior to the first Open-Label dose date. Participants with missing CDAI score at Week 8 analysis visit were imputed as not achieving CDAI Remission.
| percentage of participants | Andecaliximab 150 mg Every 2 Weeks | Andecaliximab 150 mg Weekly | Andecaliximab 300 mg Weekly | Placebo |
|---|---|---|---|---|
| Percentage of Participants Achieving CDAI Remission (CDAI ≤ 150) at Week 8 of the Double-Blind Phase | 20.8 (10.8 to 34.1) | 17.0 (8.1 to 29.8) | 11.3 (4.3 to 23.0) | 21.4 (8.3 to 41.0) |
The SES-CD evaluates 4 endoscopic variables: ulcer size, ulcerated surface, affected surface, and presence of narrowings. The SES-CD size-of-ulcer subscore ranges from 0 (none) to 3 (very large). Mucosal healing at Week 8 was defined as the size-of-ulcer subscore for segments with non-zero baseline value changes to zero at Week 8 AND the size-of-ulcer subscore for segments with zero value at baseline remain zero at Week 8. Week 8 refers to the analysis window of Day 43 to Day 70 and prior to the first Open-Label dose date. Participants with missing SES-CD size-of-ulcer subscore at Week 8 analysis visit were imputed as not achieving Mucosal Healing.
| percentage of participants | Andecaliximab 150 mg Every 2 Weeks | Andecaliximab 150 mg Weekly | Andecaliximab 300 mg Weekly | Placebo |
|---|---|---|---|---|
| Percentage of Participants Achieving Mucosal Healing (SES-CD Size-of-Ulcer Subscore = 0) at Week 8 of the Double-Blind Phase | 5.7 (1.2 to 15.7) | 1.9 (0.0 to 10.1) | 1.9 (0.0 to 10.1) | 7.1 (0.9 to 23.5) |
Collected over Double-Blind Phase: First dose of andecaliximab to Week 8; Open-Label Phase (includes adverse events occurring in the Extended Treatment Phase): First dose of open label andecaliximab to the last dose date (maximum: 200 weeks) plus 30 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Double-Blind Andecaliximab 150 mg Every 2 Weeks (Q2W) | 0/53 (0%) | 1/53 (1.9%) | 15/53 (28.3%) |
| Double-Blind Andecaliximab 150 mg Weekly (QW) | 0/53 (0%) | 6/53 (11.3%) | 25/53 (47.2%) |
| Double-Blind Andecaliximab 300 mg Weekly | 0/53 (0%) | 8/53 (15.1%) | 25/53 (47.2%) |
| Double-Blind Placebo | 0/28 (0%) | 3/28 (10.7%) | 13/28 (46.4%) |
| Open-Label Andecaliximab QW From Andecaliximab 150 mg Q2W | 0/52 (0%) | 9/52 (17.3%) | 22/52 (42.3%) |
| Open-Label Andecaliximab QW From Andecaliximab 150 mg QW | 0/48 (0%) | 10/48 (20.8%) | 21/48 (43.8%) |
| Open-Label Andecaliximab QW From Andecaliximab 300 mg QW | 0/47 (0%) | 7/47 (14.9%) | 17/47 (36.2%) |
| Open-Label Andecaliximab QW From Placebo | 0/26 (0%) | 6/26 (23.1%) | 16/26 (61.5%) |
| Event | Double-Blind Andecaliximab 150 mg Every 2 Weeks (Q2W) | Double-Blind Andecaliximab 150 mg Weekly (QW) | Double-Blind Andecaliximab 300 mg Weekly | Double-Blind Placebo | Open-Label Andecaliximab QW From Andecaliximab 150 mg Q2W | Open-Label Andecaliximab QW From Andecaliximab 150 mg QW | Open-Label Andecaliximab QW From Andecaliximab 300 mg QW | Open-Label Andecaliximab QW From Placebo |
|---|---|---|---|---|---|---|---|---|
| Crohn's diseaseGastrointestinal disorders | 0/53 | 3/53 | 2/53 | 0/28 | 4/52 | 5/48 | 4/47 | 3/26 |
| Small intestinal obstructionGastrointestinal disorders | 0/53 | 0/53 | 0/53 | 0/28 | 2/52 | 1/48 | 2/47 | 0/26 |
| AnaemiaBlood and lymphatic system disorders | 0/53 | 1/53 | 1/53 | 0/28 | 0/52 | 0/48 | 0/47 | 1/26 |
| AppendicitisInfections and infestations | 0/53 | 0/53 | 0/53 | 0/28 | 0/52 | 0/48 | 0/47 | 1/26 |
| Bacterial pyelonephritisInfections and infestations | 0/53 | 0/53 | 0/53 | 0/28 | 0/52 | 0/48 | 0/47 | 1/26 |
| NephrolithiasisRenal and urinary disorders | 0/53 | 0/53 | 0/53 | 0/28 | 0/52 | 0/48 | 0/47 | 1/26 |
| Anal fistulaGastrointestinal disorders | 0/53 | 0/53 | 1/53 | 1/28 | 0/52 | 0/48 | 0/47 | 0/26 |
| Perirectal abscessInfections and infestations | 0/53 | 0/53 | 0/53 | 1/28 | 0/52 | 0/48 | 0/47 | 0/26 |
| ParaesthesiaNervous system disorders | 0/53 | 0/53 | 0/53 | 1/28 | 0/52 | 0/48 | 0/47 | 0/26 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/53 | 0/53 | 0/53 | 1/28 | 0/52 | 0/48 | 0/47 | 0/26 |
| Event | Double-Blind Andecaliximab 150 mg Every 2 Weeks (Q2W) | Double-Blind Andecaliximab 150 mg Weekly (QW) | Double-Blind Andecaliximab 300 mg Weekly | Double-Blind Placebo | Open-Label Andecaliximab QW From Andecaliximab 150 mg Q2W | Open-Label Andecaliximab QW From Andecaliximab 150 mg QW | Open-Label Andecaliximab QW From Andecaliximab 300 mg QW | Open-Label Andecaliximab QW From Placebo |
|---|---|---|---|---|---|---|---|---|
| Crohn's diseaseGastrointestinal disorders | 1/53 | 1/53 | 2/53 | 2/28 | 6/52 | 10/48 | 4/47 | 5/26 |
| NauseaGastrointestinal disorders | 3/53 | 1/53 | 7/53 | 5/28 | 3/52 | 4/48 | 1/47 | 2/26 |
| PyrexiaGeneral disorders | 1/53 | 3/53 | 0/53 | 4/28 | 2/52 | 1/48 | 2/47 | 2/26 |
| Abdominal painGastrointestinal disorders | 1/53 | 7/53 | 4/53 | 3/28 | 7/52 | 1/48 | 3/47 | 1/26 |
| AnaemiaBlood and lymphatic system disorders | 0/53 | 2/53 | 6/53 | 0/28 | 1/52 | 1/48 | 1/47 | 1/26 |
| FatigueGeneral disorders | 6/53 | 0/53 | 5/53 | 1/28 | 1/52 | 1/48 | 0/47 | 0/26 |
| DizzinessNervous system disorders | 0/53 | 5/53 | 2/53 | 0/28 | 0/52 | 0/48 | 1/47 | 0/26 |
| HeadacheNervous system disorders | 0/53 | 4/53 | 5/53 | 1/28 | 2/52 | 1/48 | 1/47 | 0/26 |
| NasopharyngitisInfections and infestations | 2/53 | 1/53 | 4/53 | 0/28 | 4/52 | 3/48 | 4/47 | 1/26 |
| Clostridium difficile infectionInfections and infestations | 0/53 | 1/53 | 0/53 | 0/28 | 0/52 | 0/48 | 0/47 | 2/26 |
Safety Analysis Set included all participants who received at least 1 dose of study drug.
| Age, Continuous(years) | Andecaliximab 150 mg Every 2 Weeks | Andecaliximab 150 mg Weekly | Andecaliximab 300 mg Weekly | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 38 ± 12.8 | 39 ± 13.5 | 42 ± 11.7 | 38 ± 13.5 | 39 ± 12.8 |
| Sex: Female, Male(Participants) | Andecaliximab 150 mg Every 2 Weeks | Andecaliximab 150 mg Weekly | Andecaliximab 300 mg Weekly | Placebo | Total |
|---|---|---|---|---|---|
| Female | 25 | 28 | 22 | 15 | 90 |
| Male | 28 | 25 | 31 | 13 | 97 |
| Race/Ethnicity, Customized(Participants) | Andecaliximab 150 mg Every 2 Weeks | Andecaliximab 150 mg Weekly | Andecaliximab 300 mg Weekly | Placebo | Total |
|---|---|---|---|---|---|
| Race — Asian | 1 | 1 | 0 | 1 | 3 |
| Race — Black or African American | 3 | 4 | 3 | 1 | 11 |
| Race — White | 48 | 42 | 48 | 22 | 160 |
| Race — Other | 1 | 0 | 1 | 3 | 5 |
| Race — Not Permitted | 0 | 6 | 1 | 1 | 8 |
| Race/Ethnicity, Customized(Participants) | Andecaliximab 150 mg Every 2 Weeks | Andecaliximab 150 mg Weekly | Andecaliximab 300 mg Weekly | Placebo | Total |
|---|---|---|---|---|---|
| Ethnicity — Hispanic or Latino | 1 | 1 | 5 | 1 | 8 |
| Ethnicity — Not Hispanic or Latino | 52 | 46 | 47 | 26 | 171 |
| Ethnicity — Not Permitted | 0 | 6 | 1 | 1 | 8 |
| Region of Enrollment(Participants) | Andecaliximab 150 mg Every 2 Weeks | Andecaliximab 150 mg Weekly | Andecaliximab 300 mg Weekly | Placebo | Total |
|---|---|---|---|---|---|
| Hungary | 2 | 1 | 0 | 2 | 5 |
| United States | 29 | 28 | 30 | 17 | 104 |
| Czechia | 1 | 2 | 1 | 1 | 5 |
| United Kingdom | 2 | 2 | 2 | 0 | 6 |
| Spain | 3 | 0 | 2 | 0 | 5 |
| New Zealand | 4 | 1 | 0 | 0 | 5 |
| Canada | 3 | 1 | 0 | 0 | 4 |
| Poland | 3 | 5 | 6 | 2 | 16 |
| Italy | 0 | 0 | 1 | 1 | 2 |
| South Africa | 0 | 0 | 2 | 1 | 3 |
| Australia | 3 | 2 | 3 | 1 | 9 |
| France | 0 | 6 | 1 | 1 | 8 |
| Germany | 3 | 5 | 5 | 2 | 15 |
Ran from Apr 2015 to primary completion in Nov 2016, 19 months.
Results were first posted in Mar 2019, 2 years 3 months after primary completion. A results delay was requested in Feb 2017.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Andecaliximab